In order to explore the involvement these changes in the pathogenesis of diabetic nephropathy, MLN-4760 (a blocker of ACE2) was chronically (4–16 weeks) administered to animals with type I [17] and type II diabetes mellitus (DM) [38]. Here, ACE2 is linked to type 2 diabetes mellitus.